ArticleOncogene2006
Aberrant promoter methylation and silencing of the POU2F3 gene in cervical cancer.
Article in Oncogene, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 36 citations in OpenAlex.
- Utility of methylation markers in cervical cancer early detection: appraisal of the state-of-the-science.Gynecologic oncology · 2009Pooled it
- Transitioning to a Personalized Approach in Molecularly Subtyped Small-Cell Lung Cancer (SCLC).International journal of molecular sciences · 2024Review
- New insights for gynecological cancer therapies: from molecular mechanisms and clinical evidence to future directions.Cancer metastasis reviews · 2023Review
- Loss of retinoic acid receptor-related receptor alpha (Rorα) promotes the progression of UV-induced cSCC.Cell death & disease · 2021Article
- Epigenome-wide DNA methylation analysis of small cell lung cancer cell lines suggests potential chemotherapy targets.Clinical epigenetics · 2020Article
- Immune Cell Production of Interleukin 17 Induces Stem Cell Features of Pancreatic Intraepithelial Neoplasia Cells.Gastroenterology · 2018Article
- Emerging Biomarkers in Bladder Cancer Identified by Network Analysis of Transcriptomic Data.Frontiers in oncology · 2018Review
- Single-cell analyses of transcriptional heterogeneity in squamous cell carcinoma of urinary bladder.Oncotarget · 2016Article
- Susceptibility Genes for Multiple Sclerosis Identified in a Gene-Based Genome-Wide Association Study.Journal of clinical neurology (Seoul, Korea) · 2015Article
- Epigenetics and cervical cancer: from pathogenesis to therapy.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Review
- Octamer-binding transcription factors: genomics and functions.Frontiers in bioscience (Landmark edition) · 2013Review
- Article
- Genome-wide screening of genes regulated by DNA methylation in colon cancer development.PloS one · 2012Article
- Characterization of NOL7 gene point mutations, promoter methylation, and protein expression in cervical cancer.International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists · 2012Article
- The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis.BMC medical genomics · 2008Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
POU2F3 (OCT11, Skn-1a) is a keratinocyte-specific POU transcription factor whose expression is tied to squamous epithelial stratification. It is also a candidate tumor suppressor gene in cervical cancer (CC) because it lies in a critical loss of heterozygosity region on 11q23.3 in that cancer, and its expression is lost in more than 50% of CC tumors and cell lines. We now report that the loss of POU2F3 expression is tied to the hypermethylation of CpG islands in the POU2F3 promoter. Bisulfite sequencing analysis revealed that methylation of specific CpG sites (-287 to -70 bp) correlated with POU2F3 expression, which could be reactivated with a demethylating agent. Combined bisulfite restriction analysis revealed aberrant methylation of the POU2F3 promoter in 18 of 46 (39%) cervical tumors but never in normal epithelium. POU2F3 expression was downregulated and inversely correlated with promoter hypermethylation in 10 out of 11 CC cell lines. Immunohistochemical analysis on a cervical tissue microarray detected POU2F3 protein in the epithelium above the basal layer. As the disease progressed, expression also decreased, especially in invasive squamous cell cancer (70% loss). Thus, aberrant DNA methylation of the CpG island in POU2F3 promoter appears to play a key role in silencing this gene expression in human CC. The results suggested that POU2F3 might be one of the CC-related tumor suppressor genes, which are disrupted by both epigenetic and genetic mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.